“Innovation Reduction Act" — something funny & poignant from one of our final fellowship sessions this summer. Honored to host Tamar Thompson (Alexion, MassBio), who shared how to champion patient access & innovation. Learn more: nopatientleftbehind.org/fellowship #Advocacy #HealthPolicy

Excited to be hosting Building Medicines: Resilience Across the Product Lifecycle with Nucleate Bay Area Area at San Francisco @techweek_ 🌱 Medicines don’t grow on trees. Behind every cure is a journey of discovery, battles & breakthroughs. 🍸 Panel + networking happy hour.

No one pretends to have asthma for an inhaler. 💰 But families still face copays—after paying premiums. Lifesaving inhalers should cost low or $0 out-of-pocket. ⚖️ Let’s #FixInsurance: nopatientleftbehind.org/fixinsurance #AffordableAccess #Asthma #DrugPricing

There’s no crystal ball in biomedical innovation. Investors, scientists and entrepreneurs constantly bet on uncertain science, hoping today’s discovery becomes tomorrow’s treatment. Most don’t make it. But when one does, patients benefit and society wins. That’s why the “pill

The IRA’s “pill penalty” is more than a technicality. It tilts incentives against small molecule drug innovation, generics, competition, and post-approval research. We need to align small molecule “negotiation” w/ biologics & rethink CBO’s models.